The development of positron emission tomography tracers for in vivo targeting the kinase domain of the epidermal growth factor receptor
A Högnäsbacka, AJ Poot, DJ Vugts… - Pharmaceuticals, 2022 - mdpi.com
Multiple small molecule PET tracers have been developed for the imaging of the epidermal
growth factor receptor (EGFR). These tracers target the tyrosine kinase (TK) domain of the …
growth factor receptor (EGFR). These tracers target the tyrosine kinase (TK) domain of the …
PET imaging of lung cancers in precision medicine: current landscape and future perspective
Q Wang, X Zhang, W Wei, M Cao - Molecular Pharmaceutics, 2022 - ACS Publications
Despite the recent advances in cancer treatment, lung cancer remains the leading cause of
cancer mortality worldwide. Immunotherapies using immune checkpoint inhibitors (ICIs) …
cancer mortality worldwide. Immunotherapies using immune checkpoint inhibitors (ICIs) …
[HTML][HTML] miR-767-3p inhibits growth and migration of lung adenocarcinoma cells by regulating CLDN18
YL Wan, HJ Dai, W Liu, HT Ma - Oncology Research, 2018 - ncbi.nlm.nih.gov
Abstract Claudin18 (CLDN18) is necessary for intercellular junctions and is reported to be
involved in cell migration and metastasis, making it like an oncogene in various cancer …
involved in cell migration and metastasis, making it like an oncogene in various cancer …
Development of a fluorinated analogue of erlotinib for PET imaging of EGFR mutation–positive NSCLC
O Shamni, H Grievink, B Itamar, E Mishani… - Molecular Imaging and …, 2019 - Springer
Purpose Positron emission tomography (PET) using [11 C] erlotinib identifies non-small cell
lung carcinoma (NSCLC) tumors with activating mutations in the epidermal growth factor …
lung carcinoma (NSCLC) tumors with activating mutations in the epidermal growth factor …
PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy
A Makino, A Miyazaki, A Tomoike, H Kimura… - Bioorganic & Medicinal …, 2018 - Elsevier
Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR-TKIs) are used as
molecular targeted therapy for non-small cell lung cancer (NSCLC) patients. The therapy is …
molecular targeted therapy for non-small cell lung cancer (NSCLC) patients. The therapy is …
Identifying nonsmall‐cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging
JL Goggi, A Haslop, B Ramasamy… - Journal of Labelled …, 2019 - Wiley Online Library
Specific mutations significantly affect response to epidermal growth factor tyrosine kinase
inhibitor (EGFR‐TKI) treatment in lung cancer patients. Identifying patients with these …
inhibitor (EGFR‐TKI) treatment in lung cancer patients. Identifying patients with these …
Noninvasive in vivo mapping of intracellular signaling proteins using a pairing of targeted and untargeted fluorescently labeled small molecule kinase inhibitors
KM Tichauer, L Wang, A Solanki… - … Drug Distribution in …, 2020 - spiedigitallibrary.org
Small molecule kinase inhibitors (SMKIs) drugs have the potential to offer exquisite
specificity in controlling aberrant intracellular signaling pathways in cancer and other …
specificity in controlling aberrant intracellular signaling pathways in cancer and other …